ResMed Inc. (NYSE:RMD) Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. lowered its holdings in ResMed Inc. (NYSE:RMD) by 2.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 56,478 shares of the medical equipment provider’s stock after selling 1,400 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in ResMed were worth $13,787,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of RMD. OFI Invest Asset Management acquired a new stake in ResMed in the second quarter valued at $32,000. Versant Capital Management Inc lifted its holdings in ResMed by 196.7% in the second quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 120 shares during the period. Financial Connections Group Inc. acquired a new position in shares of ResMed during the 2nd quarter worth $37,000. Blue Trust Inc. raised its stake in shares of ResMed by 182.7% during the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 137 shares during the last quarter. Finally, Rothschild Investment LLC acquired a new position in shares of ResMed during the 2nd quarter worth $44,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insiders Place Their Bets

In other ResMed news, CEO Michael J. Farrell sold 14,683 shares of ResMed stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $214.25, for a total transaction of $3,145,832.75. Following the sale, the chief executive officer now directly owns 440,799 shares of the company’s stock, valued at approximately $94,441,185.75. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Kaushik Ghoshal sold 5,000 shares of the stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the completion of the sale, the insider now owns 21,788 shares in the company, valued at $5,502,777.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael J. Farrell sold 14,683 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $214.25, for a total transaction of $3,145,832.75. Following the completion of the transaction, the chief executive officer now owns 440,799 shares in the company, valued at approximately $94,441,185.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 75,874 shares of company stock worth $17,731,782 over the last quarter. Company insiders own 0.71% of the company’s stock.

ResMed Stock Down 0.3 %

RMD opened at $243.61 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91. The company has a market capitalization of $35.76 billion, a PE ratio of 32.27, a price-to-earnings-growth ratio of 1.79 and a beta of 0.69. The business has a 50-day moving average of $242.99 and a 200-day moving average of $220.75. ResMed Inc. has a fifty-two week low of $140.81 and a fifty-two week high of $260.49.

ResMed (NYSE:RMD) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.17. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The company’s revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.64 EPS. Equities research analysts forecast that ResMed Inc. will post 9.22 EPS for the current fiscal year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 0.87%. The ex-dividend date is Thursday, November 7th. ResMed’s dividend payout ratio (DPR) is presently 28.08%.

Analysts Set New Price Targets

RMD has been the subject of several research reports. Robert W. Baird lifted their price target on ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Wolfe Research reiterated an “underperform” rating and issued a $180.00 price target on shares of ResMed in a report on Wednesday, September 18th. KeyCorp boosted their target price on ResMed from $251.00 to $266.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research report on Friday, October 25th. Finally, Royal Bank of Canada upped their price target on shares of ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $225.70.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.